Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy (Q46707992)

24 December 2017

title

Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy (English)

1 reference

24 December 2017

0 references

1 reference

1 reference

1 reference

Pieber TR

1

1 reference

24 December 2017

Treichel HC

2

1 reference

24 December 2017

Hompesch B

3

1 reference

24 December 2017

Philotheou A

4

1 reference

24 December 2017

Mordhorst L

5

1 reference

24 December 2017

Gall MA

6

1 reference

24 December 2017

Robertson LI

7

1 reference

24 December 2017

publication date

22 March 2007

1 reference

24 December 2017

published in

Diabetic Medicine

1 reference

24 December 2017

volume

24

1 reference

24 December 2017

issue

6

1 reference

24 December 2017

page(s)

635-642

1 reference

24 December 2017

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02113.X

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02113.X

The effects of improved glycemic control on complications in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02113.X

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02113.X

Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02113.X

Insulin glargine: a systematic review of a long-acting insulin analogue

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02113.X

A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02113.X

Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02113.X

Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02113.X

Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02113.X

Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02113.X

Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02113.X

Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02113.X

Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02113.X

The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02113.X

Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02113.X

Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02113.X

Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02113.X

Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02113.X

Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02113.X

Management of dyslipidemia in children and adolescents with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02113.X

Efficacy of conversion from bedtime NPH insulin injection to once- or twice-daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02113.X

Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02113.X

Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02113.X

Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02113.X

Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02113.X

Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02113.X

The Mechanism of Protraction of Insulin Detemir, a Long-Acting, Acylated Analog of Human Insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02113.X

10.1111/J.1464-5491.2007.02113.X

21 January 2018

Identifiers

DOI

1 reference

24 December 2017

1 reference

24 December 2017